Comorbidity
Disease4 papers3 findingsMeSH D015897
- Humans4
Associations
2Mortality
upin humans2
2 studies
Mortality
upin humans2
Comorbidity raises the risk of mortality in humans (aHR = 1.7 95% CI = 0.9-3.1).
Humanshigh vs. low comorbidity count ≥ 3 vs. < 3median follow-up of 9.3 yearsn = 874
Hearing Loss as a Modifier of the Association Between Comorbidities and Mortality · Journal of the American Geriatrics Society · 11 Sep 2026
Comorbidity raises the risk of mortality in humans.
Humanship fractureat least 10 yearsn = 1,840
Mortality and Risk Factors After Hip Fracture in Patients Aged 50 Years and Older: A Minimum 10-Year Follow-up Using Jeju Island Cohort Study · Journal of Korean medical science · 7 Sep 2026
Higher-burden trajectories
upin humans1
1 study
Higher-burden trajectories
upin humans1
Comorbidity is associated with higher-burden trajectories in humans (up to 1.57 per condition).
Humanshigher-burden trajectoriesn = 23,376
Multisite pain follows five trajectories in older Chinese adults · European journal of pain (London, England) · 30 Sep 2026
Funding
National Institute on AgingUS$1.1mNational Institute on Drug AbuseUS$980.3kNational Institute of General Medical SciencesUS$2.4m10 grants since 2007
Unravelling genetic basis of comorbidity using EHR-linked biobank data
National Institute of General Medical SciencesUniversity of PennsylvaniaUS$2.4m2026–2030
Tracking HIV Infection & Alcohol Abuse CNS Comorbidity with Neuroimaging
National Institute on Alcohol Abuse and AlcoholismSRI InternationalUS$893.4k2007–2028
Comorbidities and other consequences at the intersection of the HIV and substance use epidemics
National Institute on Drug AbuseUniversity of WashingtonUS$684.4k2023–2028
Expanding our understanding of polygenic disease comorbidity structure: PRSxPheWAS
National Human Genome Research InstituteVanderbilt University Medical CenterUS$437.5k2026–2028
National Institute on AgingMassachusetts General HospitalUS$594.7k2022–2027
National Institute on AgingBrown UniversityUS$536.3k2022–2027
Optimizing diabetes treatment strategies in complex comorbidity
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of California Los AngelesUS$166k2024–2029
Epigenetic Risk Scoring for Polysubstance Use and Comorbidity in People with HIV
National Institute on Drug AbuseHenry Ford Health + Michigan State University Health SciencesUS$295.9k2026–2028
Theoretically Informed Behavioral Intervention to Enhance QOL and Prevent HIV-related Comorbidities
National Institute on Minority Health and Health DisparitiesYale UniversityUS$1.2m2024–2029
Latest
717Larger lung artery volume tied to deaths in smokers without COPD
Each roughly 25-millilitre increase in artery volume was linked to a death-rate ratio of 1.42 in one cohort and 1.23 in another.Each roughly 25-millilitre increase in artery volume was linked to a death-rate ratio of 1.42 in one cohort and 1.23 in another.
Metformin linked to fewer clots in blood cancer and diabetes
Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.Metformin users had lower blood clot risk than non-users, with a hazard ratio of 0.78, a measure comparing risk over time.
Model predicted frailty risk in older emergency patients
The model achieved a discrimination score of 0.940 in 143 patients set aside for testing, in a retrospective study of older emergency patients.The model achieved a discrimination score of 0.940 in 143 patients set aside for testing, in a retrospective study of older emergency patients.
US sudden cardiac death rate linked to high potassium rose
After accounting for age, the rate rose from 0.65 deaths per 100,000 in 1999 to 1.32 in 2020 in US mortality records.After accounting for age, the rate rose from 0.65 deaths per 100,000 in 1999 to 1.32 in 2020 in US mortality records.
From prematurity and low birth weight to CKD: opportunities for intervention
Generalised myasthenia gravis linked to higher death risk
Medicare beneficiaries with the disease had 8% higher mortality risk at 12 months than those without myasthenia gravis.Medicare beneficiaries with the disease had 8% higher mortality risk at 12 months than those without myasthenia gravis.